5igl: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of the second bromodomain of human TAF1L in complex with bromosporine (BSP)== | ==Crystal structure of the second bromodomain of human TAF1L in complex with bromosporine (BSP)== | ||
<StructureSection load='5igl' size='340' side='right' caption='[[5igl]], [[Resolution|resolution]] 2.10Å' scene=''> | <StructureSection load='5igl' size='340' side='right'caption='[[5igl]], [[Resolution|resolution]] 2.10Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5igl]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5IGL OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[5igl]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5IGL OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5IGL FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMF:BROMOSPORINE'>BMF</scene></td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.1Å</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMF:BROMOSPORINE'>BMF</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5igl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5igl OCA], [https://pdbe.org/5igl PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5igl RCSB], [https://www.ebi.ac.uk/pdbsum/5igl PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5igl ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/TAF1L_HUMAN TAF1L_HUMAN] May act as a functional substitute for TAF1/TAFII250 during male meiosis, when sex chromosomes are transcriptionally silenced.<ref>PMID:12217962</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 22: | Line 23: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: | [[Category: Arrowsmith CH]] | ||
[[Category: Edwards | [[Category: Bountra C]] | ||
[[Category: Felletar | [[Category: Edwards AM]] | ||
[[Category: Filippakopoulos | [[Category: Felletar I]] | ||
[[Category: Knapp | [[Category: Filippakopoulos P]] | ||
[[Category: Krojer | [[Category: Knapp S]] | ||
[[Category: Picaud | [[Category: Krojer T]] | ||
[[Category: Picaud S]] | |||
[[Category: Tallant | [[Category: Tallant C]] | ||
[[Category: | [[Category: Von Delft F]] | ||
Latest revision as of 16:51, 30 August 2023
Crystal structure of the second bromodomain of human TAF1L in complex with bromosporine (BSP)Crystal structure of the second bromodomain of human TAF1L in complex with bromosporine (BSP)
Structural highlights
FunctionTAF1L_HUMAN May act as a functional substitute for TAF1/TAFII250 during male meiosis, when sex chromosomes are transcriptionally silenced.[1] Publication Abstract from PubMedBromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET (bromo and extra-terminal) inhibitors and their significant activity in diverse tumor models have rapidly translated into clinical studies and have motivated drug development efforts targeting non-BET BRDs. However, the complex multidomain/subunit architecture of BRD protein complexes complicates predictions of the consequences of their pharmacological targeting. To address this issue, we developed a promiscuous BRD inhibitor [bromosporine (BSP)] that broadly targets BRDs (including BETs) with nanomolar affinity, creating a tool for the identification of cellular processes and diseases where BRDs have a regulatory function. As a proof of principle, we studied the effects of BSP on leukemic cell lines known to be sensitive to BET inhibition and found, as expected, strong antiproliferative activity. Comparison of the modulation of transcriptional profiles by BSP after a short exposure to the inhibitor resulted in a BET inhibitor signature but no significant additional changes in transcription that could account for inhibition of other BRDs. Thus, nonselective targeting of BRDs identified BETs, but not other BRDs, as master regulators of context-dependent primary transcription response. Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.,Picaud S, Leonards K, Lambert JP, Dovey O, Wells C, Fedorov O, Monteiro O, Fujisawa T, Wang CY, Lingard H, Tallant C, Nikbin N, Guetzoyan L, Ingham R, Ley SV, Brennan P, Muller S, Samsonova A, Gingras AC, Schwaller J, Vassiliou G, Knapp S, Filippakopoulos P Sci Adv. 2016 Oct 12;2(10):e1600760. eCollection 2016 Oct. PMID:27757418[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||